CN103608343B - 用于制备作为大麻素受体调节剂的稠合氮杂环的晶形和制备方法 - Google Patents

用于制备作为大麻素受体调节剂的稠合氮杂环的晶形和制备方法 Download PDF

Info

Publication number
CN103608343B
CN103608343B CN201280020512.3A CN201280020512A CN103608343B CN 103608343 B CN103608343 B CN 103608343B CN 201280020512 A CN201280020512 A CN 201280020512A CN 103608343 B CN103608343 B CN 103608343B
Authority
CN
China
Prior art keywords
pyrazine
diaza
amide
crystalline form
hydroxymethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201280020512.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN103608343A (zh
Inventor
A.C.布莱克本
韩相敦
R.M.琼斯
安东尼奥·加利多·蒙塔尔班
B.B.帕尔
J.K.鲁特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arena Pharmaceuticals Inc
Original Assignee
Arena Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharmaceuticals Inc filed Critical Arena Pharmaceuticals Inc
Publication of CN103608343A publication Critical patent/CN103608343A/zh
Application granted granted Critical
Publication of CN103608343B publication Critical patent/CN103608343B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201280020512.3A 2011-02-25 2012-02-24 用于制备作为大麻素受体调节剂的稠合氮杂环的晶形和制备方法 Expired - Fee Related CN103608343B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161446732P 2011-02-25 2011-02-25
US61/446,732 2011-02-25
US201161448542P 2011-03-02 2011-03-02
US61/448,542 2011-03-02
PCT/US2012/026506 WO2012116276A1 (en) 2011-02-25 2012-02-24 Crystalline forms and processes for the preparation of condensed azacycles ( cannabinoid receptor modulators)

Publications (2)

Publication Number Publication Date
CN103608343A CN103608343A (zh) 2014-02-26
CN103608343B true CN103608343B (zh) 2019-02-01

Family

ID=45841624

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280020512.3A Expired - Fee Related CN103608343B (zh) 2011-02-25 2012-02-24 用于制备作为大麻素受体调节剂的稠合氮杂环的晶形和制备方法

Country Status (20)

Country Link
US (4) US9458136B2 (enExample)
EP (3) EP4166552B1 (enExample)
JP (1) JP5945554B2 (enExample)
KR (1) KR102036932B1 (enExample)
CN (1) CN103608343B (enExample)
AU (1) AU2012222146B2 (enExample)
BR (1) BR112013021549B1 (enExample)
CA (1) CA2827057C (enExample)
CL (1) CL2013002436A1 (enExample)
CO (1) CO6852066A2 (enExample)
DK (1) DK3395812T3 (enExample)
EA (1) EA035989B1 (enExample)
ES (1) ES2932441T3 (enExample)
IL (1) IL227782A (enExample)
MX (1) MX346533B (enExample)
MY (1) MY165767A (enExample)
PH (1) PH12013501726A1 (enExample)
SG (1) SG192817A1 (enExample)
WO (1) WO2012116276A1 (enExample)
ZA (1) ZA201306402B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ598288A (en) 2009-08-28 2014-02-28 Arena Pharm Inc Cannabinoid receptor modulators
US9597340B2 (en) 2011-02-25 2017-03-21 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
ES2929977T3 (es) 2011-02-25 2022-12-05 Arena Pharm Inc Moduladores del receptor cannabinoide
CA2827057C (en) 2011-02-25 2022-06-07 Arena Pharmaceuticals, Inc. Crystalline forms and processes for the preparation of condensed azacycles (cannabinoid receptor modulators)
WO2016085941A1 (en) * 2014-11-25 2016-06-02 Arena Pharmaceuticals, Inc. Processes for the preparation of cannabinoid receptor modulators
UA124626C2 (uk) * 2016-04-10 2021-10-20 Арена Фармасьютікалз, Інк. СПОСОБИ ЛІКУВАННЯ СЕЛЕКТИВНИМИ АГОНІСТАМИ РЕЦЕПТОРА СВ<sub>2</sub>
KR20200005614A (ko) 2017-05-08 2020-01-15 아레나 파마슈티칼스, 인크. 내장 통증의 치료를 위한 화합물 및 방법
WO2018208847A1 (en) 2017-05-08 2018-11-15 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of pain from inflammatory bowel disease
CN114391011A (zh) * 2019-09-12 2022-04-22 四川海思科制药有限公司 一种六氢化苯并吡唑衍生物及其制备
WO2023059610A1 (en) 2021-10-05 2023-04-13 Arena Pharmaceuticals, Inc. Crystalline forms and processes for the preparation of cannabinoid receptor modulators

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006030124A1 (fr) * 2004-09-13 2006-03-23 Sanofi-Aventis Derives de pyrazole condense, leur preparation et leur application en therapeutique.
CN101238107A (zh) * 2005-06-02 2008-08-06 格兰马克药品股份有限公司 新的大麻素受体配体，含有该配体的药物组合物及其制备方法
CN102596913A (zh) * 2009-08-28 2012-07-18 艾尼纳制药公司 大麻素受体调节剂

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3964478B2 (ja) 1995-06-30 2007-08-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬
IL145922A0 (en) 1999-04-28 2002-07-25 Aventis Pharma Gmbh Di-aryl acid derivatives as ppar receptor ligands
US20040259936A1 (en) 2001-12-07 2004-12-23 Nagarkatti Leonard C Treatment of neoplasia
SE0300010D0 (sv) 2003-01-07 2003-01-07 Astrazeneca Ab Novel Compounds
WO2005123677A1 (en) 2004-06-16 2005-12-29 Actelion Pharmaceuticals Ltd 4-carbonyl substituted 1,1,2-trimethyl-1a,4,5,5a-tetrahydro-1h-4-aza-cyclopropa'a!pentalene derivatives as agonists for the g-protein-coupled receptor s1p1/edg1 and immunosuppressive agents
WO2006025069A2 (en) 2004-07-12 2006-03-09 Cadila Healthcare Limited Tricyclic pyrazole derivatives as cannabinoid receptor modulators
DE102004054666A1 (de) 2004-11-12 2006-05-18 Bayer Cropscience Gmbh Substituierte Pyrazol-3-carboxamide, Verfahren zur Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren
PE20060949A1 (es) 2004-12-23 2006-10-11 Arena Pharm Inc Derivados fusionados de pirazol como agonistas del receptor de niacina
EP1902034B1 (en) * 2005-06-02 2011-03-30 Glenmark Pharmaceuticals S.A. Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
EA200970080A1 (ru) 2006-07-04 2009-06-30 Янссен Фармацевтика Нв Бензимидазольные агонисты каннабиноидов, содержащие замещенную гетероциклическую группу
JP5030114B2 (ja) 2006-09-25 2012-09-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体をモジュレートする化合物
US8481574B2 (en) 2006-10-12 2013-07-09 Abbott Laboratories Compounds as cannabinoid receptor ligands
US7928103B2 (en) 2006-10-17 2011-04-19 Boehringer Ingelheim International Gmbh Compounds which modulate the CB2 receptor
CA2668491A1 (en) 2006-11-03 2008-05-08 Glenmark Pharmaceuticals S.A. Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and processes for their preparation
WO2008064054A2 (en) 2006-11-21 2008-05-29 Boehringer Ingelheim International Gmbh Compounds which modulate the cb2 receptor
WO2008079316A1 (en) 2006-12-20 2008-07-03 Cara Therapeutics, Inc. Tetrahydroquinolinones, tetrahydronaphthyridones and derivatives thereof
WO2008085302A1 (en) 2006-12-20 2008-07-17 Merck & Co., Inc. Imidazopyridine analogs as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases
US20080214537A1 (en) 2007-03-02 2008-09-04 Cara Therapeutics, Inc. Bridged phenanthridines
JP5185924B2 (ja) 2007-03-16 2013-04-17 京セラ株式会社 誘電体磁器およびコンデンサ
ES2548764T3 (es) 2007-03-30 2015-10-20 Janssen Pharmaceutica N.V. Agonistas de cannabinoides de bencimidazol
US20090209536A1 (en) 2007-06-17 2009-08-20 Kalypsys, Inc. Aminoquinazoline cannabinoid receptor modulators for treatment of disease
BRPI0812504B8 (pt) 2007-06-21 2021-05-25 Cara Therapeutics Inc composto para profilaxia ou tratamento de doença ou condição associada a receptor de canabinoides em sujeito mamífero
US8338623B2 (en) 2007-07-09 2012-12-25 Abbvie Inc. Compounds as cannabinoid receptor ligands
US7943658B2 (en) 2007-07-23 2011-05-17 Bristol-Myers Squibb Company Indole indane amide compounds useful as CB2 agonists and method
WO2009025785A2 (en) 2007-08-21 2009-02-26 Merck & Co., Inc. Cb2 receptor ligands for the treatment of pain
UA104010C2 (en) 2008-12-18 2013-12-25 Эли Лилли Энд Компани Purine compounds
WO2010088050A2 (en) 2009-01-28 2010-08-05 Cara Therapeutics, Inc. Bicyclic pyrazolo-heterocycles
US7741350B1 (en) * 2009-01-28 2010-06-22 Cara Therapeutics, Inc. Bicyclic pyrazolo-heterocycles
CA2827057C (en) 2011-02-25 2022-06-07 Arena Pharmaceuticals, Inc. Crystalline forms and processes for the preparation of condensed azacycles (cannabinoid receptor modulators)
ES2929977T3 (es) * 2011-02-25 2022-12-05 Arena Pharm Inc Moduladores del receptor cannabinoide
US9597340B2 (en) 2011-02-25 2017-03-21 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
WO2012116278A1 (en) 2011-02-25 2012-08-30 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006030124A1 (fr) * 2004-09-13 2006-03-23 Sanofi-Aventis Derives de pyrazole condense, leur preparation et leur application en therapeutique.
CN101238107A (zh) * 2005-06-02 2008-08-06 格兰马克药品股份有限公司 新的大麻素受体配体，含有该配体的药物组合物及其制备方法
CN102596913A (zh) * 2009-08-28 2012-07-18 艾尼纳制药公司 大麻素受体调节剂

Also Published As

Publication number Publication date
CA2827057C (en) 2022-06-07
US20170144993A1 (en) 2017-05-25
EP3395812B1 (en) 2022-09-28
NZ614787A (en) 2014-08-29
EP4166552B1 (en) 2025-03-19
EA201391233A1 (ru) 2014-02-28
EP4166552A1 (en) 2023-04-19
BR112013021549A2 (pt) 2016-11-01
IL227782A0 (en) 2013-09-30
US20140135345A1 (en) 2014-05-15
PH12013501726A1 (en) 2014-01-13
JP2014506602A (ja) 2014-03-17
CL2013002436A1 (es) 2014-01-24
ES2932441T3 (es) 2023-01-19
US9458136B2 (en) 2016-10-04
MY165767A (en) 2018-04-23
AU2012222146A1 (en) 2013-09-19
MX346533B (es) 2017-03-14
MX2013009760A (es) 2014-06-11
JP5945554B2 (ja) 2016-07-05
CN103608343A (zh) 2014-02-26
US10183930B2 (en) 2019-01-22
IL227782A (en) 2017-02-28
AU2012222146B2 (en) 2017-05-11
US20210380560A1 (en) 2021-12-09
DK3395812T3 (da) 2022-11-28
KR102036932B1 (ko) 2019-10-25
KR20140025353A (ko) 2014-03-04
US11560369B2 (en) 2023-01-24
BR112013021549B1 (pt) 2022-01-11
CA2827057A1 (en) 2012-08-30
EP3395812A1 (en) 2018-10-31
WO2012116276A1 (en) 2012-08-30
CO6852066A2 (es) 2014-01-30
US20190308952A1 (en) 2019-10-10
EP3395812B8 (en) 2022-11-02
US10981895B2 (en) 2021-04-20
EP2678330A1 (en) 2014-01-01
SG192817A1 (en) 2013-09-30
EA035989B1 (ru) 2020-09-09
ZA201306402B (en) 2022-03-30

Similar Documents

Publication Publication Date Title
US11560369B2 (en) Crystalline forms and processes for the preparation of cannabinoid receptor modulators
EP4114391B1 (en) Compositions for use in a method of treating an estrogen receptor associated cancer
US9765063B2 (en) Amido compounds as RORγt modulators and uses thereof
JP2022066289A (ja) カンナビノイド受容体モジュレーター
CN1671639A (zh) 新型联苯大麻素和类似联苯的大麻素
TW201100400A (en) Piperazine compound capable of inhibiting prostaglandin d synthase
JP2013532657A (ja) 環式ｎ，ｎ’−ジアリールチオ尿素及びｎ，ｎ’−ジアリール尿素−アンドロゲン受容体アンタゴニスト、抗癌剤、その調製のための方法及び使用
EP3781165A1 (en) Aminopyrazines and related compounds useful as mitochondrial uncouplers
CN105308040B (zh) 1,3-二氨基环戊烷甲酰胺衍生物
TW202128161A (zh) 用於靶向病原性血管之化合物及方法
CN104955809B (zh) 取代的乙炔衍生物及其作为mGluR4的正变构调节剂的用途
TW201704206A (zh) 環狀化合物
WO2020215157A1 (en) Non-peptidic heterocycle-containing compounds for the treatment of alzheimer&#39;s disease
JP2017511348A (ja) Ｂｃｒ−Ａｂｌ二倍体の阻害剤、その調製方法及びその用途
HK1263040A1 (en) Crystalline forms and processes for the preparation of condensed azacycles (cannabinoid receptor modulators)
JP2007262022A (ja) 新規２−チオフェンカルボキサミド誘導体
WO2016085941A1 (en) Processes for the preparation of cannabinoid receptor modulators
CN103797007A (zh) 新合成方法
US20230416191A1 (en) Compounds, Compositions and Methods for the Treatment of CREB-dependent Diseases
NZ614787B2 (en) Crystalline forms and processes for the preparation of condensed azacycles ( cannabinoid receptor modulators)
CN108368139A (zh) 取代的恶唑烷酮化合物及其应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
CB03 Change of inventor or designer information

Inventor after: A.C. Blackburn

Inventor after: Han Xiangdun

Inventor after: R.M. Jones

Inventor after: Antonio Garrido Montalban

Inventor after: B.B. Parr

Inventor after: J.K. Rutter

Inventor before: A.C. Blackburn

Inventor before: Han Xiangdun

Inventor before: R.M. Jones

Inventor before: Montalban Antonio Garrido

Inventor before: B.B. Parr

Inventor before: J.K. Rutter

CB03 Change of inventor or designer information
COR Change of bibliographic data

Free format text: CORRECT: INVENTOR; FROM: BLACKBURN ANTHONY C. HAN SANGDON R.M.JONES MONTALBAN ANTHONIO GARRIDO PAL BIMAN B. RUETER JAIMIE KARYN TO: BLACKBURN ANTHONY C. HAN SANGDON R.M.JONES PAL BIMAN B. RUETER JAIMIE KARYN

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20190201

CF01 Termination of patent right due to non-payment of annual fee